Human insulin biosimilar - Marvel Lifesciences

Drug Profile

Human insulin biosimilar - Marvel Lifesciences

Alternative Names: Solumarv

Latest Information Update: 05 Oct 2016

Price : $50

At a glance

  • Originator Marvel LifeSciences Private Limited
  • Class Antihyperglycaemics; Insulins; Pancreatic hormones
  • Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Submission Withdrawal Diabetes mellitus

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 20 Nov 2015 The Committee for Medicinal Products for Human Use (CHMP) does not recommend approval of Solumarv for Diabetes mellitus in European Union
  • 01 Nov 2015 Preregistration for Diabetes mellitus in European Union (IV) before November 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top